< Terug naar vorige pagina
Onderzoeker
Yani Berckmans
- Disciplines:Kankertherapie
Affiliaties
- Laboratorium voor Tumorimmunologie en Immunotherapie (Afdeling)
Lid
Vanaf1 sep 2021 → Heden
Projecten
1 - 1 of 1
- Preklinische evaluatie van nieuwe radionucliden als behandeling voor kankerVanaf8 jul 2021 → HedenFinanciering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
Publicaties
1 - 6 van 6
- TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice.(2024)
Auteurs: Yani Berckmans, Jolien Ceusters, Ignace Vergote, An Coosemans
Pagina's: 1147 - Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model.(2024)
Auteurs: Yani Berckmans, Kim De Keersmaecker, An Coosemans
Pagina's: 381 - 397 - Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates(2023)
Auteurs: Yani Berckmans, Yannick Hoffert, Erwin Dreesen, An Coosemans
- Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer(2021)
Auteurs: Jenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, Yani Berckmans, Roxanne Wouters, Thaïs Baert, Tom Bourne, Wouter Froyman, Dominique Schols, Patrizia Agostinis, et al.
- Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy
Auteurs: Yani Berckmans, Jolien Ceusters, Roxanne Wouters, An Coosemans
- Intraperitoneal alpha therapy with 224Ra-labeled microparticles combined with chemotherapy in an ovarian cancer mouse model
Auteurs: Roxanne Wouters, Yani Berckmans, Jolien Ceusters, Ignace Vergote, An Coosemans